Related Experiment Video
Updated: May 9, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Infant neurodevelopment following in utero exposure to antidepressant medication
Marie-Paule Austin1, Janan C Karatas, Parag Mishra
1St John of God Health Care, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia; Royal Hospital for Women, Randwick, NSW, Australia.
Insights
Pregnancy antidepressant exposure, primarily serotonin reuptake inhibitors, did not show adverse effects on infant neurodevelopment at 18 months. These findings support continued use of antidepressants during pregnancy for maternal mental health.
Area of Science:
- Neuroscience
- Developmental Psychology
- Pharmacology
Background:
- Maternal mental health is crucial during pregnancy.
- Antidepressant use during pregnancy raises concerns about infant neurodevelopmental outcomes.
- Existing research provides mixed evidence on the long-term effects of prenatal antidepressant exposure.
Purpose of the Study:
- To investigate the impact of prenatal antidepressant exposure on infant neurodevelopment at 18 months of age.
- To assess cognitive, motor, and language development in infants exposed to antidepressants in utero.
- To provide data for clinicians and mothers regarding antidepressant use during pregnancy.
Main Methods:
- A prospective, longitudinal study design.
- Inclusion of 35 antidepressant-exposed and 23 nonexposed infants.
- Utilized the Bayley Scales of Infant Development (BSID-III) at 18 months for neurodevelopmental assessment.
- Collected data on maternal factors including mood disorder, IQ, and psychosocial status.
Main Results:
- Nearly 90% of exposed infants received therapeutic antidepressant doses throughout the second and third trimesters.
- No significant differences in cognitive, motor, or language outcomes were observed between exposed and unexposed infants.
- Maternal depression around birth or up to 18 months did not correlate with infant neurodevelopmental outcomes.
Conclusions:
- Prenatal exposure to antidepressants, predominantly selective serotonin reuptake inhibitors, is not associated with poorer infant neurodevelopmental outcomes at 18 months.
- These findings align with previous studies, supporting informed decision-making for antidepressant use in pregnancy.
- The study's small sample size and heterogeneity necessitate cautious interpretation of the results.
Aim:
To examine the impact of pregnancy exposure to antidepressants on infant neurodevelopment.
Methods:
A prospective, longitudinal study in which antidepressant-exposed (n = 35) and nonexposed (n = 23) infants were administered the Bayley Scales of Infant Development (BSID-III) at 18 months, which measures neurodevelopment across five domains. Data on obstetric and perinatal complications, maternal IQ, presence of mood disorder in pregnancy and up to and including 18 months, and psychosocial status were also collected.
Results:
Almost 90% of infants were exposed throughout the second and third trimesters to therapeutic antidepressant doses. Bivariate analysis showed no difference between exposed and unexposed infants in any of the neurodevelopmental outcomes. Maternal depression around birth or up to time of developmental testing was not associated with neurodevelopmental outcomes.
Conclusion:
Our results suggest that pregnancy antidepressant exposure (mostly serotonin reuptake inhibitors) is not associated with poorer cognitive, motor or language development outcomes in infants at 18 months. This information supports earlier studies and adds into the available data used by clinicians and mothers making key decisions around the use of antidepressants in pregnancy. However, given the small sample size, and some degree of heterogeneity in terms of antidepressant exposure, these results need to be treated with caution.
Related Concept Videos
01:07Teratogenicity
01:25Antidepressant Drugs: Overview